Nonadherence to GLP‐1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Obesity Reviews · 26.07.2026
DOI: 10.1111/obr.70200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Reviews, online erschienen am 26.07.2026. Verfasst von Efrata A Shegena und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Glucagon‐like peptide 1 (GLP‐1) agonists are widely used for obesity management in patients with or without diabetes. However, treatment persistence is often limited due to adverse drug reactions (ADRs). Understanding adherence patterns in randomized controlled trials (RCTs) is crucial for predicting real‐world treatment acceptance.
Objective
To estimate the pooled nonadherence rates and reasons for nonadherence to GLP‐1 agonists in overweight or patients with obesity participating in RCTs.
Methods
A systematic review and meta‐analysis of RCTs was conducted to evaluate nonadherence to GLP‐1 receptor agonists. A literature search was performed in PubMed, Embase, and Web of Science from inception to October 2, 2024. Studies were included if they evaluated GLP‐1 receptor agonists for overweight or obesity management and reported adherence outcomes.
Results
The pooled RR for nonadherence to GLP‐1 receptor agonists was 0.63 (95% CI: 0.48, 0.82, p = 0.01), indicating a 37% lower risk of nonadherence compared with the control group. However, ADR‐induced nonadherence was significantly higher in the GLP‐1 group (RR: 2.29 [95% CI: 1.47, 3.56, p = 0.04]), particularly due to gastrointestinal side effects. Nonadherence due to loss to follow‐up was lower in the GLP‐1 group (RR: 0.43 [95% CI: 0.27, 0.71, p = 0.18]).
Conclusion
GLP‐1 receptor agonists were associated with a lower overall nonadherence rate in RCTs compared with control treatments, suggesting higher persistence. However, ADR‐related nonadherence was significantly higher, particularly due to gastrointestinal side effects. These findings highlight the need for strategies to improve treatment tolerability and adherence in real‐world settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Department of Pharmacy, Debre Markos University, Debre Markos, Ethiopia.
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
- Public Health Program, School of Health Systems & Innovation, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota, USA.
- School of Pharmacy, The University of Texas, El Paso, Texas, USA.
ORCID-Profile: Efrata A Shegena, Muktar Ahmed, Akshaya Srikanth Bhagavathula
Zitieren
APA
Shegena, E. A., Kiflu, M., Ahmed, M., Bhagavathula, A. S., & Abegaz, T. M. (2026). Nonadherence to GLP‐1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Obesity Reviews. https://doi.org/10.1111/obr.70200
Vancouver
Shegena EA, Kiflu M, Ahmed M, Bhagavathula AS, Abegaz TM. Nonadherence to GLP‐1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Obesity Reviews. 2026. doi:10.1111/obr.70200
BibTeX
@article{Shegena2026,
author = {Shegena, Efrata A and Kiflu, Mekdes and Ahmed, Muktar and Bhagavathula, Akshaya Srikanth and Abegaz, Tadesse M},
title = {Nonadherence to GLP‐1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Obesity Reviews},
year = {2026},
doi = {10.1111/obr.70200}
}
EUVIMED